The U.S. Federal Trade Commission and the Justice Department imposed $12 million in civil penalties on Edwards Lifesciences and Genesis Medtech Group over alleged efforts to evade Hart-Scott-Rodino (HSR) premerger filing requirements. Regulators said the deal was effectively a single transaction split into a $115 million acquisition of JC Medical plus a $25 million investment in Genesis, intended to stay below the $119.5 million reporting threshold. The judgment also includes five years of mandatory prior notice, compliance obligations and other restrictions, underscoring tighter U.S. scrutiny of medical device M&A without triggering immediate moves in individual stocks or major indexes.